|
【结 构 式】 
|
【分子编号】66664 【品名】(R)-5-(tert-butoxy)-3-((tert-butyldimethylsilyl)oxy)-5-oxopentanoic acid 【CA登记号】 |
【 分 子 式 】C15H30O5Si 【 分 子 量 】318.4857 【元素组成】C 56.57% H 9.49% O 25.12% Si 8.82% |
与该中间体有关的原料药合成路线共 1 条
合成路线1
该中间体在本合成路线中的序号：(II)
| 【1】 Balanov A, Shenkar N, Niddam-Hildeshehnv. 2007. Process for producing rousuvastatin. W0 2007041666(本专利属于Teva Pharmaceutical Industries Ltd．Isnel; Teva Pharmaceuticals USA, Inc) |
| 【2】 Hiddam-Hijldesheim V, Balanov A, Shenkar N, et al. 2006. Preparation of rosuvastatin. W0 2006091771 (本专利属于Teva Pharmaceutial Industries Ltd，Israel; Teva Pharmaceuticals USA, Inc) |
| 中间体序号 | 中间体编号 | 品名 | CAS号 | 分子式 | 供应商 | 用于合成 |
|---|---|---|---|---|---|---|
| (I) | 66663 | (R)-1-tert-butyl 5-ethyl 3-((tert-butyldimethylsilyl)oxy)pentanedioate | C17H34O5Si | 详情 | 详情 | |
| (II) | 66664 | (R)-5-(tert-butoxy)-3-((tert-butyldimethylsilyl)oxy)-5-oxopentanoic acid | C15H30O5Si | 详情 | 详情 | |
| (III) | 66665 | (S)-5-(tert-butoxy)-3-((tert-butyldimethylsilyl)oxy)-5-oxopentanoic propionic anhydride | C18H34O6Si | 详情 | 详情 | |
| (IV) | 66666 | (R)-tert-butyl 3-((tert-butyldimethylsilyl)oxy)-6-(diethoxyphosphoryl)-5-oxohexanoate | C20H41O7PSi | 详情 | 详情 | |
| (V) | 23882 | N-[4-(4-fluorophenyl)-5-formyl-6-isopropyl-2-pyrimidinyl]-N-methylmethanesulfonamide | 147118-37-4 | C16H18FN3O3S | 详情 | 详情 |
| (VI) | 66667 | (R,E)-tert-butyl 2-((tert-butyldimethylsilyl)oxy)-6-(4-(4-fluorophenyl)-6-isopropyl-2-(N-methylmethylsulfonamido)pyrimidin-5-yl)-4-oxohex-5-enoate | C31H46FN3O6SSi | 详情 | 详情 | |
| (VII) | 66662 | (R,E)-tert-butyl 6-(4-(4-fluorophenyl)-6-isopropyl-2-(N- methylmethylsulfonamido)pyrimidin-5-yl)-2-hydroxy-4-oxohex-5-enoate | C25H32FN3O6S | 详情 | 详情 | |
| (VIII) | 66668 | (2R,4S,E)-tert-butyl 6-(4-(4-fluorophenyl)-6-isopropyl-2-(N-methylmethylsulfonamido)pyrimidin-5-yl)-2,4-dihydroxyhex-5-enoate | C25H34FN3O6S | 详情 | 详情 |
Extended Information